IR thematic call on alirocumab



Sanofi and Regeneron hosted an IR Thematic Conference Call for the financial community focusing on alirocumab during the European Society of Cardiology Congress in Barcelona.

Alirocumab (SAR236553/ REGN727) is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) for the reduction of LDL-cholesterol. Alirocumab is currently being evaluated in a large Phase 3 program in patients with hypercholesterolemia.